Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that ER positive, HER2-negative status confers therapeutic sensitivity to Letrozole in patients with Invasive Breast Carcinoma.
The Republic of Ireland's Health Products Regulatory Authority (HPRA) has authorized letrozole for the neo-adjuvant treatment of patients who are postmenopausal women with hormone receptor positive, HER-2 negative breast cancer where chemotherapy is not suitable and immediate surgery is not indicated.
This statement is based on a regulatory approval from the Health Products Regulatory Authority:
Neo-adjuvant treatment of postmenopausal women with hormone receptor positive, HER-2 negative breast cancer where chemotherapy is not suitable and immediate surgery not indicated.